4 Participants Needed

18F-Clofarabine PET Imaging for Cancer

OM
RV
Overseen ByRoberto Vargas, MD
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Roberto Vargas
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the drug 18F-Clofarabine for cancer treatment?

Clofarabine, a component of 18F-Clofarabine, has shown effectiveness in treating blood cancers like acute myeloid leukemia and acute lymphoblastic leukemia, and it has been approved for use in certain pediatric leukemia cases. Additionally, combining clofarabine with imaging techniques has shown promise in liver cancer studies, suggesting potential for broader cancer applications.12345

Is 18F-Clofarabine safe for humans?

Clofarabine has been used in various studies for treating leukemia, showing some common side effects like low blood cell counts, nausea, and liver enzyme changes. Serious side effects were less common, but included conditions like capillary leak syndrome and liver issues. Overall, it has been considered to have an acceptable safety profile in heavily pretreated patients.35678

How is the drug 18F-Clofarabine unique for cancer treatment?

18F-Clofarabine is unique because it is used as a PET imaging probe to measure the expression of a specific enzyme (deoxycytidine kinase) in tumors, which can help predict how well a tumor will respond to certain cancer drugs. This imaging approach is different from traditional treatments as it focuses on assessing the tumor's characteristics rather than directly treating the cancer.123910

Research Team

RV

Roberto Vargas, MD

Principal Investigator

Cleveland Clinic, Case Comprehensive Cancer Center

Eligibility Criteria

This trial is for adults over 18 with metastatic carcinoma or adenocarcinoma, confirmed by imaging. Participants must have measurable disease, be able to stay still for an hour during imaging, and have normal organ function levels. It's not suitable for those with recent severe heart issues, significant bleeding, stroke risks, or pregnant/breastfeeding women.

Inclusion Criteria

I am over 18 years old.
I can stay still for up to an hour for a scan.
My cancer is confirmed as carcinoma or adenocarcinoma.
See 5 more

Exclusion Criteria

Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
I have not had any major heart problems in the last 6 months.
Pregnancy or breastfeeding

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Observation

Participants receive a CFA injection and undergo a PET/CT scan to measure DCK activity. They are observed for side effects.

1 day
1 visit (in-person)

Follow-up

Participants are contacted the next day to inquire about any side effects. If routine care involves repeat imaging, the CFA PET/CT scan may be repeated up to 365 days later.

up to 12 months
1 follow-up contact (virtual), potential additional imaging visits

Treatment Details

Interventions

  • 18F-Clofarabine
Trial OverviewThe study tests if a new PET/CT imaging agent called 18F-Clofarabine (CFA) can effectively image cancer metabolism related to pyrimidine metabolism—a factor in how well certain cancer drugs work.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: 18F-ClofarabineExperimental Treatment1 Intervention
18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy

Find a Clinic Near You

Who Is Running the Clinical Trial?

Roberto Vargas

Lead Sponsor

Trials
1
Recruited
4+

Omar Mian

Lead Sponsor

Trials
2
Recruited
20+

Findings from Research

Clofarabine is an effective treatment for hematologic malignancies, including acute lymphoblastic leukemia and acute myeloid leukemia, and is already approved for use in pediatric patients after two prior therapies.
Clinical trials indicate that clofarabine works well both alone and in combination with other drugs for adult myeloid leukemia, showing promise particularly in older patients and those with challenging genetic profiles.
Clofarabine: a new treatment option for patients with acute myeloid leukemia.Larson, ML., Venugopal, P.[2018]
Clofarabine is a second-generation purine nucleoside analogue that effectively inhibits DNA polymerases and ribonucleotide reductase, leading to apoptosis in both cycling and non-cycling cells.
It was approved by the FDA in 2004 for treating pediatric patients with relapsed or refractory acute lymphoblastic leukemia after at least two prior chemotherapy regimens, demonstrating its efficacy in hematological malignancies.
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.Lech-Maranda, E., Korycka, A., Robak, T.[2019]
Clofarabine, a treatment for acute leukemia, shows a median cerebrospinal fluid (CSF) penetration of only 5%, indicating limited ability to reach the central nervous system, but the levels achieved may still be cytotoxic in vitro.
In a study involving four nonhuman primates, clofarabine demonstrated a median clearance rate of 17 mL/min/kg and a terminal half-life of 105 minutes, suggesting a relatively quick elimination from the body.
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.Berg, SL., Bonate, PL., Nuchtern, JG., et al.[2018]

References

Clofarabine: a new treatment option for patients with acute myeloid leukemia. [2018]
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. [2019]
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. [2018]
[18F] Clofarabine for PET Imaging of Hepatocellular Carcinoma. [2020]
Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. [2021]
Clofarabine: in pediatric patients with acute lymphoblastic leukemia. [2018]
Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. [2018]
Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. [2019]
Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. [2020]
Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity. [2018]